119 related articles for article (PubMed ID: 2835444)
1. Pharmacology and phase I/II study of continuous intravenous infusions of iododeoxyuridine and hyperfractionated radiotherapy in patients with glioblastoma multiforme.
Kinsella TJ; Collins J; Rowland J; Klecker R; Wright D; Katz D; Steinberg SM; Glastein E
J Clin Oncol; 1988 May; 6(5):871-9. PubMed ID: 2835444
[TBL] [Abstract][Full Text] [Related]
2. National Cancer Institute (phase II) study of high-grade glioma treated with accelerated hyperfractionated radiation and iododeoxyuridine: results in anaplastic astrocytoma.
Sullivan FJ; Herscher LL; Cook JA; Smith J; Steinberg SM; Epstein AH; Oldfield EH; Goffman TE; Kinsella TJ; Mitchell JB
Int J Radiat Oncol Biol Phys; 1994 Oct; 30(3):583-90. PubMed ID: 7928489
[TBL] [Abstract][Full Text] [Related]
3. Treatment of locally advanced cancer of the head and neck with 5'-iododeoxyuridine and hyperfractionated radiation therapy: measurement of cell labeling and thymidine replacement.
Epstein AH; Lebovics RS; Goffman T; Teague D; Fuetsch ES; Glatstein E; Okunieff P; Cook JA
J Natl Cancer Inst; 1994 Dec; 86(23):1775-80. PubMed ID: 7966416
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up on National Cancer Institute Phase I/II study of glioblastoma multiforme treated with iododeoxyuridine and hyperfractionated irradiation.
Goffman TE; Dachowski LJ; Bobo H; Oldfield EH; Steinberg SM; Cook J; Mitchell JB; Katz D; Smith R; Glatstein E
J Clin Oncol; 1992 Feb; 10(2):264-8. PubMed ID: 1310102
[TBL] [Abstract][Full Text] [Related]
5. Phase I clinical and pharmacological study of iododeoxyuridine and bleomycin in patients with advanced cancer.
Schilsky RL; Janisch L; Berezin F; Mick R; Vogelzang NJ; Ratain MJ
Cancer Res; 1993 Mar; 53(6):1293-6. PubMed ID: 7680282
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacology of 5-iodo-2'-deoxyuridine and 5-iodouracil and endogenous pyrimidine modulation.
Klecker RW; Jenkins JF; Kinsella TJ; Fine RL; Strong JM; Collins JM
Clin Pharmacol Ther; 1985 Jul; 38(1):45-51. PubMed ID: 4006375
[TBL] [Abstract][Full Text] [Related]
7. A phase I study of intravenous iododeoxyuridine as a clinical radiosensitizer.
Kinsella TJ; Russo A; Mitchell JB; Collins JM; Rowland J; Wright D; Glatstein E
Int J Radiat Oncol Biol Phys; 1985 Nov; 11(11):1941-6. PubMed ID: 2997090
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of intraperitoneal iododeoxyuridine with and without intravenous high-dose folinic acid in the treatment of advanced malignancies primarily confined to the peritoneal cavity: flow cytometric and pharmacokinetic analysis.
Morgan RJ; Newman EM; Doroshow JH; McGonigle K; Margolin K; Raschko J; Chow W; Somlo G; Leong L; Tetef M; Shibata S; Hamasaki V; Carroll M; Vasilev S; Akman S; Coluzzi P; Wagman L; Longmate J; Paz B; Yen Y; Klevecz R
Cancer Res; 1998 Jul; 58(13):2793-800. PubMed ID: 9661893
[TBL] [Abstract][Full Text] [Related]
9. Leucovorin modulation of 5-iododeoxyuridine radiosensitization: a phase I study.
McGinn CJ; Kunugi KA; Tutsch KD; Feierabend C; Alberti D; Lindstrom MJ; Wilding G; Arzoomanian RZ; Kinsella TJ
Clin Cancer Res; 1996 Aug; 2(8):1299-305. PubMed ID: 9816300
[TBL] [Abstract][Full Text] [Related]
10. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer.
Choi NC; Herndon JE; Rosenman J; Carey RW; Chung CT; Bernard S; Leone L; Seagren S; Green M
J Clin Oncol; 1998 Nov; 16(11):3528-36. PubMed ID: 9817271
[TBL] [Abstract][Full Text] [Related]
11. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
12. Continuous 28-day iododeoxyuridine infusion and hyperfractionated accelerated radiotherapy for malignant glioma: a phase I clinical study.
Schulz CA; Mehta MP; Badie B; McGinn CJ; Robins HI; Hayes L; Chappell R; Volkman J; Binger K; Arzoomanian R; Simon K; Alberti D; Feierabend C; Tutsch KD; Kunugi KA; Wilding G; Kinsella TJ
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1107-15. PubMed ID: 15234045
[TBL] [Abstract][Full Text] [Related]
13. Preoperative radiation therapy and iododeoxyuridine for large retroperitoneal sarcomas.
Robertson JM; Sondak VK; Weiss SA; Sussman JJ; Chang AE; Lawrence TS
Int J Radiat Oncol Biol Phys; 1995 Jan; 31(1):87-92. PubMed ID: 7995772
[TBL] [Abstract][Full Text] [Related]
14. Intravenous delivery of 5'-iododeoxyuridine during hyperfractionated radiotherapy for locally advanced head and neck cancers: results of a pilot study.
Epstein AH; Lebovics RS; Van Waes C; Smith J; Okunieff P; Cook JA
Laryngoscope; 1998 Jul; 108(7):1090-4. PubMed ID: 9665262
[TBL] [Abstract][Full Text] [Related]
15. Iododeoxyuridine (IUdR) combined with radiation in the treatment of malignant glioma: a comparison of short versus long intravenous dose schedules (RTOG 86-12).
Urtasun RC; Cosmatos D; DelRowe J; Kinsella TJ; Lester S; Wasserman T; Fulton DS
Int J Radiat Oncol Biol Phys; 1993 Sep; 27(2):207-14. PubMed ID: 8407393
[TBL] [Abstract][Full Text] [Related]
16. Measurement of thymidine replacement in patients with high grade gliomas, head and neck tumors, and high grade sarcomas after continuous intravenous infusions of 5-iododeoxyuridine.
Cook JA; Glass J; Lebovics R; Bobo H; Pass H; DeLaney TF; Oldfield EH; Mitchell JB; Glatstein E; Goffman TE
Cancer Res; 1992 Feb; 52(3):719-25. PubMed ID: 1732059
[TBL] [Abstract][Full Text] [Related]
17. Halogenated pyrimidines as radiosensitizers in the treatment of glioblastoma multiforme.
Jackson D; Kinsella T; Rowland J; Wright D; Katz D; Main D; Collins J; Kornblith P; Glatstein E
Am J Clin Oncol; 1987 Oct; 10(5):437-43. PubMed ID: 2821790
[TBL] [Abstract][Full Text] [Related]
18. Hyperfractionated radiation therapy and bis-chlorethyl nitrosourea in the treatment of malignant glioma--possible advantage observed at 72.0 Gy in 1.2 Gy B.I.D. fractions: report of the Radiation Therapy Oncology Group Protocol 8302.
Nelson DF; Curran WJ; Scott C; Nelson JS; Weinstein AS; Ahmad K; Constine LS; Murray K; Powlis WD; Mohiuddin M
Int J Radiat Oncol Biol Phys; 1993 Jan; 25(2):193-207. PubMed ID: 8380567
[TBL] [Abstract][Full Text] [Related]
19. A phase I study of intraarterial iododeoxyuridine in patients with colorectal liver metastases.
Chang AE; Collins JM; Speth PA; Smith R; Rowland JB; Walton L; Begley MG; Glatstein E; Kinsella TJ
J Clin Oncol; 1989 May; 7(5):662-8. PubMed ID: 2709091
[TBL] [Abstract][Full Text] [Related]
20. Concomitant chemoradiotherapy, neutron boost, and adjuvant chemotherapy for anaplastic astrocytoma and glioblastoma multiforme.
Krishnasamy S; Vokes EE; Dohrmann GJ; Mick R; Garcia JC; Kolker JD; Wollmann RL; Hekmatpanah J; Weichselbaum RR
Cancer Invest; 1995; 13(5):453-9. PubMed ID: 7552809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
